New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the most benefits of a ...

In one of the largest studies of early cardiogenic shock (CS) patients, where blood flow is still functioning to vital organs, researchers demonstrated that 26% experienced worse outcomes, including ...